Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia

Bibliography

• Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye (Lond) 2010;24:203-13
   PubMed Web of Science ®Google Scholar
• Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy 2013;33:838-55
   PubMed Web of Science ®Google Scholar
• Kato A, Yasukawa T, Ogura Y. Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: search for the optimized treatment regimen. Taiwan J Ophthalmol 2014;4:3-8
   Google Scholar
• Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 2014;59:1-18
   PubMed Web of Science ®Google Scholar
• Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2012;250:1717-23
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Jo Y, Ikuno Y. Transient choroidal thinning after intravitreal bevacizumab injection for myopic choroidal neovascularization. J Clin Exp Ophthalmol 2011;2:165
   Google Scholar
• Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 2010;51:3721-5
   PubMed Web of Science ®Google Scholar
• Ng DS, Kwok AK, Chan CW. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 2012;40:e98-e110
   PubMed Web of Science ®Google Scholar
• Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013;33:1375-92
   PubMed Web of Science ®Google Scholar
• El-Mollayess GM, Noureddine BN, Bashshur ZF. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 2011;26:69-76
   PubMed Web of Science ®Google Scholar
• Walia S, Varma P. Bevacizumab (Avastin) for ocular disorders. Int J Pharm Res 2013;3:59-68
   Google Scholar
• Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400
   PubMed Web of Science ®Google Scholar
• Issa PC, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration – current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2011;249:163-74
   PubMed Web of Science ®Google Scholar
• Gohel PS, Mandava N, Olson JL, Durairaj PD. Age-related macular degeneration: an update on treatment. Am J Med 2008;121:279-81
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63
   PubMed Web of Science ®Google Scholar
• Luthert PJ. Pathogenesis of age-related macular degeneration. Diagn Histopathol 2011;17:10-16
   Google Scholar
• Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93
   PubMed Web of Science ®Google Scholar
• Freund KB, Mrejen S, Gallego-Pinazo R. Current strategies for the management of treatment-resistant neovascular age-related macular degeneration. Curr Ophthalmol Rep 2014;2:6-13
   Google Scholar
• Patel K, Chow C, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013;27:663-8
   PubMed Web of Science ®Google Scholar
• Rush RB, Simunovic MP, Vandiver L, et al. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Retina 2013;34:846-52
   Web of Science ®Google Scholar
• Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-73
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Bor E, Bourla DH, et al. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina 2012;32:1811-20
   PubMed Web of Science ®Google Scholar
• El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Intravitreal Bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity. Retina 2013;33:1828-35
   PubMed Web of Science ®Google Scholar
• Leydolt C, Michels S, Prager F, et al. Effect of intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol 2010;88:594-600
   PubMed Web of Science ®Google Scholar
• El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol 2012;153:481-9
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Falcao MS, Brandao EM, Falcao-Reis FM. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina 2010;30:85-92
   PubMed Web of Science ®Google Scholar
• Alkin Z, Ozkaya A, Osmanbasoglu OA, et al. The role of epiretinal membrane on treatment of neovascular age-related macular degeneration with intravitreal bevacizumab. ScientificWorldJournal 2013;2013:958724
   PubMedGoogle Scholar
• Jonas JB, Libondi T, Golubkina L, et al. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol 2010;88:630-4
   PubMed Web of Science ®Google Scholar
• el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:779-84
   PubMed Web of Science ®Google Scholar
• Yoshizawa C, Saito W, Hirose S, et al. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Jpn J Ophthalmol 2013;57:68-73
   PubMed Web of Science ®Google Scholar
• Hara R, Kawaji T, Inomata Y, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol 2010;248:931-6
   PubMed Web of Science ®Google Scholar
• Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9-25
   PubMed Web of Science ®Google Scholar
• Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525
   PubMed Web of Science ®Google Scholar
• Introini U, Casalino G, Querques G, et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye (Lond) 2012;26:976-82
   PubMed Web of Science ®Google Scholar
• Foster P, Jiang Y. Epidemiology of myopia. Eye (Lond) 2014;28:202-8
   PubMed Web of Science ®Google Scholar
• Guo X, Xiao X, Li S, et al. Nonsyndromic high myopia in a Chinese family mapped to MYP1: linkage confirmation and phenotypic characterization. Arch Ophthalmol 2010;128:1473-9
   PubMed Web of Science ®Google Scholar
• Ratnamala U, Lyle R, Rawal R, et al. Refinement of the X-linked nonsyndromic high-grade myopia locus MYP1 on Xq28 and exclusion of 13 known positional candidate genes by direct sequencing. Invest Ophthalmol Vis Sci 2011;52:6814-19
   PubMed Web of Science ®Google Scholar
• Inhoffen W, Ziemssen F. [Morphological features of myopic choroidal neovascularization: differences to neovascular age-related macular degeneration]. Ophthalmologe 2012;109:749-57
   PubMed Web of Science ®Google Scholar
• Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol 2013;155:913-19
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia (protocol). Cochrane Database Syst Rev 2014
   Google Scholar
• Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012;32:1547-52
   PubMed Web of Science ®Google Scholar
• Rinaldi M, Chiosi F, Dell’omo R, et al. Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study. Retina 2013;33:397-402
   PubMed Web of Science ®Google Scholar
• Kitagawa T, Yuzawa M. [Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study]. Nippon Ganka Gakkai Zasshi 2013;117:344-50
   PubMedGoogle Scholar
• Kitagawa T, Yuzawa M. [Comparison of 1-year treatment outcome of intravitreal pegaptanib sodium versus bevacizumab for myopic choroidal neovascularization]. Nippon Ganka Gakkai Zasshi 2013;117:727-34
   PubMedGoogle Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-92
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:e1-1
   PubMedGoogle Scholar
• Milani P, Massacesi A, Ciaccia S, et al. Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization. Clin Ophthalmol 2011;6:1885-94
   Google Scholar
• Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012;96:1068-72
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010;248:937-41
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina 2013;33:593-7
   PubMed Web of Science ®Google Scholar
• Chen CH, Wu PC, Chen YJ, et al. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 2011;27:395-400
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011;249:595-9
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta ophthalmol 2012;90:e82-3
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010;128:437-42
   PubMed Web of Science ®Google Scholar
• Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010;94:864-70
   PubMed Web of Science ®Google Scholar
• Saviano S, Piermarocchi R, Leon PE, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. Int J Ophthalmol 2014;7:335
   Web of Science ®Google Scholar
• Desco MC, Mataix J, Garcia-Pous M, et al. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up. Retina 2011;31:475-81
   PubMed Web of Science ®Google Scholar
• Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010;248:543-50
   PubMed Web of Science ®Google Scholar
• Liang IC, Chang YY, Lee TS, et al. Treatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin®). Int Ophthalmol 2014;34:971-7
   PubMedGoogle Scholar
• Ehlken C, Jungmann S, Bohringer D, et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 2014;28:538-45
   PubMed Web of Science ®Google Scholar
• Joussen AM, Bornfeld N. The treatment of wet age-related macular degeneration. Dtsch Arztebl Int 2009;65:3
   Google Scholar
• Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 2012;12:1299-313
   PubMed Web of Science ®Google Scholar
• Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375-86
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787-94
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9
   PubMed Web of Science ®Google Scholar
• Zhang XY, Guo XF, Zhang SD, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol 2014;7:355-64
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-71
   PubMed Web of Science ®Google Scholar
• Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 2014. [ Epub ahead of print]
   Google Scholar
• Abdollahi M, Shafiee A, Bathaiee FS, et al. Drug-induced toxic reactions in the eye: an overview. J Infus Nurs 2004;2:386-98
   Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42(1):D1091-7
   PubMedGoogle Scholar
• Iwata E, Ueno S, Ishikawa K, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53:4185-90
   PubMed Web of Science ®Google Scholar
• Tao Y, Libondi T, Jonas JB. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration. J Ocul Pharmacol Ther 2010;26:79-84
   PubMed Web of Science ®Google Scholar
• Coppens G, Angulo Bocco M, Spielberg L, Leys A. Intravitreal bevacizumab for myopic choroidal neovascularization: 1-year and 2-year results. Bull Soc Belge Ophtalmol 2010;315:39-45
   PubMedGoogle Scholar
• Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 2012;47:28-33
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30:1609-15
   PubMed Web of Science ®Google Scholar
• Loh BK, Lee SY, Cheng J, et al. Intravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population. Ann Acad Med Singapore 2010;39:493
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 2011;31:1841-7
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Tsujikawa A, Yodoi Y, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011;25:375-81
   PubMed Web of Science ®Google Scholar